Press Room

Share

House Committee Passes Legislation Aimed at Improving Health Outcomes for Ohioans

Today, the House Insurance Committee passed legislation that would increase access to biomarker testing.

June 12, 2024

The following is a statement from Leo Almeida, government relations director, American Cancer Society Cancer Action Network (ACS CAN)

 

COLUMBUS, OHIO – “Today, the House Insurance Committee passed legislation that would increase access to biomarker testing. This legislation will help address a significant barrier and bring the promise of precision medicine to more Ohioans, no matter their income or where they live. Biomarker testing opens the door to targeted therapies, which can provide many benefits to patients, including better outcomes, improved quality of life, and, in some cases, reduced costs from bypassing ineffective therapies.

“ACS CAN extends its gratitude to Rep. White for sponsoring this critical next step in ensuring cancer patients have access to precision medicine and looks forward to seeing the full House pass this vital legislation soon.” 

More Press Releases AboutAccess to Biomarker Testing, Ohio

Media Contacts

Michelle Zimmerman
Associate Director, Regional Media Advocacy
[email protected]
Cell: 740.525.9577

Related Press Releases

December 17, 2024

Biomarker Testing Bill Passes Assembly Hurdle, Vote Follows Testimony from Breast Cancer Survivors

This week, New Jersey lawmakers approved legislation to improve access to biomarker testing with a unanimous vote by the Assembly Appropriations Committee. Assembly Bill 4163 now awaits a vote on the Assembly floor. The Senate advanced identical legislation (Senate Bill 3098) in the Senate Commerce Committee last week, which now awaits further consideration by the Senate Budget & Appropriations Committee. Advocates with the New Jersey Biomarker Testing Coalition are hopeful that the bills will receive the necessary support to secure swift passage in the new year.

Read More
December 12, 2024

NJ Senate Commerce Committee Advances Biomarker Testing Bill

Earlier today, Senate Bill 3098 was unanimously voted out of the Senate Commerce Committee. This legislation, which aims to ensure that biomarker testing is covered by Medicaid and all other state-regulated insurance plans when patients need it, now advances to the Senate Budget & Appropriations Committee for further consideration. In October, the Assembly Financial Institutions & Insurance Committee approved identical legislation (Assembly Bill 4163), which now awaits a hearing in the Assembly Appropriations Committee.

Read more
December 4, 2024

Calls to Improve Access to Biomarker Testing in NJ Bring Together Patients, Providers & Public Health Leaders across Disease Spectrum

Key public health, patient and provider groups have come out in support of improving access to biomarker testing in New Jersey, urging lawmakers to advance and pass Assembly Bill 4163 / Senate Bill 3098 this legislative session. This fall, a broad coalition of over 30 organizations, medical leaders and patient advocates wrote to members of the Assembly Financial Institutions & Insurance (AFI) Committee to vote in favor of A4163, which they did—unanimously—several weeks ago. Now, the New Jersey Biomarker Coalition is looking to the Assembly Appropriations and Senate Commerce Committees to take up this bill and follow the lead of their AFI member colleagues.

Read more